Paula T. Trzepacz
Corporate Officer/Principal bei The Indiana University School of Medicine
Profil
Paula T.
Trzepacz is a Clinical Professor at The Indiana University School of Medicine, where she has been employed since 2004.
She previously served as the Chief Medical Officer & Executive Vice President at Neurotrope, Inc. and Synaptogenix, Inc. in 2016.
She was also a Professor at the University of Mississippi Medical Center and an Associate Professor at the University of Pittsburgh School of Medicine.
Trzepacz holds a doctorate from Dartmouth College and an undergraduate degree from Wellesley College.
Aktive Positionen von Paula T. Trzepacz
| Unternehmen | Position | Beginn |
|---|---|---|
| The Indiana University School of Medicine | Corporate Officer/Principal | 01.01.2004 |
Ehemalige bekannte Positionen von Paula T. Trzepacz
| Unternehmen | Position | Ende |
|---|---|---|
| SYNAPTOGENIX, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2016 |
| University of Mississippi Medical Center | Corporate Officer/Principal | - |
| University of Pittsburgh School of Medicine | Corporate Officer/Principal | - |
| NEUROTROPE, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Paula T. Trzepacz
| Wellesley College | Undergraduate Degree |
| Dartmouth College | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SYNAPTOGENIX, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Neurotrope, Inc.
 Neurotrope, Inc. Pharmaceuticals: MajorHealth Technology Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY. | Health Technology |
